RTTNews | Jan 11, 2021 07:55AM EST

07:54 Monday, January 11, 2021 (RTTNews.com) - Cytokinetics, Incorporated (CYTK) announced the FDA has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy. The company anticipates results from REDWOOD-HCM, ongoing phase 2 clinical trial, in mid-year.

Fady Malik, Cytokinetics' Executive Vice President of Research & Development, said: "It's a promising time to develop investigational medicines for patients with HCM who currently have no FDA approved medical therapy available to treat the underlying hypercontractility associated with their disease."

CK-274 is a small molecule cardiac myosin inhibitor arising from an extensive chemical optimization program conducted with careful attention to therapeutic index and pharmacokinetic properties that may translate into next-in-class potential in clinical development.

Read the original article on RTTNews ( https://www.rttnews.com/3159362/cytokinetics-ck-274-receives-orphan-drug-designation-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved